ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0052

Treatment of Hepatorenal Syndrome Type 1 with Terlipressin Reduces Need for Renal Replacement Therapy After Liver Transplantation

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Velez, Juan Carlos Q., Ochsner Health System, New Orleans, Louisiana, United States
  • Sclair, Seth, University Hospitals Cleveland Medical Center Department of Orthopaedics, Cleveland, Ohio, United States
  • Sanchez, Antonio J., University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
  • Caldwell, Stephen, University of Virginia, Charlottesville, Virginia, United States
  • Sigal, Samuel, Montefiore Medical Center, Bronx, New York, United States
  • Thuluvath, Paul J., Mercy Medical Center & University of Maryland School of Medicine, Baltimore, Maryland, United States
  • Satoskar, Rohit, MedStar Georgetown University Hospital, Washington, District of Columbia, United States
  • Pappas, S. Chris, Orphan Therapeutics, Lebanon, New Jersey, United States
  • Jamil, Khurram, Mallinckrodt Pharmaceuticals Specialty Brands Principal Office, Bedminster, New Jersey, United States

Hepatorenal syndrome type 1 (HRS-1) is a severe but reversible acute kidney injury in patients with cirrhosis. The need for renal replacement therapy (RRT) posttransplant is associated with prolonged intensive care unit stays and decreased survival. Recently, a randomized placebo (PBO)-controlled trial (CONFIRM, NCT02770716) demonstrated the efficacy of terlipressin (TERLI) for inducing reversal of HRS-1 and reducing the cumulative need for RRT. This study assessed whether TERLI reduces the rate of RRT following liver transplantation (LT).


CONFIRM was a North American trial (N=300) that compared HRS-1 reversal rates between patients treated 2:1 with albumin plus TERLI (n=199) or albumin plus PBO (n=101). In a post hoc analysis, we assessed the rate of RRT post-LT by intention-to-treat analysis through 90 days of follow-up. We also conducted a pooled analysis of the 3 TERLI RCTs in HRS-1 (OT-0401 [NCT00089570], REVERSE [NCT01143246], and CONFIRM) to examine 90-day overall and RRT-free survival rates in patients who received LT.


In CONFIRM, 23.1% (46/199) of patients in the TERLI group and 28.7% (29/101) of patients in the PBO group underwent LT. Following LT, the rate of post-LT RRT in patients who received TERLI was significantly lower than that in those who received PBO (19.6% [9/46] vs 44.8% [13/29], respectively; P=0.036). The overall 90-day survival rate for those transplanted in the TERLI group was 100% (46/46) compared with 93.1% (27/29) in the PBO group (P=not significant). Further, in the pooled analysis of the 3 phase 3 studies, the 90-day survival rates were 98.9% (93/94) and 91.0% (71/78), respectively (P=0.014). In the pooled analysis of REVERSE and CONFIRM, for transplant-listed patients, 50.0% (46/92) of patients in the TERLI group were alive without RRT at Day 90 compared with 32.2% (19/59) in the PBO group (P=0.032).


Treatment with TERLI added to albumin for patients with HRS-1 significantly decreases the need for RRT following LT.